NIH/PHS Invention Disclosures, December 9, 1996
Text of a Federal Register notice submitted by NIH for publication on December 10, 1996
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health
ACTION: Notice
The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.
ADDRESS: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7057; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
4'- And 4',4"-Substituted-3a(diphenylmethoxy)tropane Analogs As Cocaine Therapeutics
AH Newman, AC Allen, RH Kline, S Izenwasser, JL Katz (NIDA)
Serial No. 08/667,024 filed 20 Jun 96 (claiming benefit of 60/000,378 filed 21 Jun 95)
Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext. 223
The invention provides a series of 4'- and 4',4"-substituted benztropine analogs that demonstrate high affinity binding (K1<30 nM) to the dopamine transporter and bind selectively (>100-fold) over the other monoamine transporters. These compounds block dopamine reuptake in vitro and yet do not demonstrate a cocaine-like behavioral profile in animal models of psychomotor stimulant abuse. Structure-Activity Relationships suggest that these compounds interact at a binding domain that differs from that of cocaine at the dopamine transporter. The invention also describes cocaine analogs comprising N-substituted 2',3' and 3',3" and 3',4"- analogs, which exhibit a cocaine-like behavioral profile. One of the compounds exhibits cocaine-like activity and anti-muscarinic receptor activity, which may improve its therapeutic utility. These compounds represent an unprecedented class of dopamine uptake inhibitors that may have potential as cocaine-abuse therapeutics, since they have neurochemical similarities to cocaine and yet do not appear to have abuse liability. Further, radiolabeled analogs will be suitable for imaging the dopamine transporter in mammalian brain using SPECT and PET and thus would be useful in the diagnoses and monitoring of neurodegenerative disorders involving the dopaminergic system (e.g., Parkinson's disease). In addition, the invention provides pharmaceutical compositions comprising an analog of the invention and a pharmaceutically acceptable carrier excipient. (portfolios: Central Nervous System - Therapeutics, psychotherapeutics, drug dependence; Central Nervous System - Therapeutics, neurological, antiparkinsonian; Central Nervous System - Diagnostics, in vivo)
Conjugate Vaccine For Nontypeable Haemophilus Influenzae
X-X Gu (NIDCD), C-M Tsai (CBER), DJ Lim (NIDCD), JB Robbins (NICHD)
Serial No. 60/016,020 filed 23 Apr 96
Licensing Contact: Elaine Gese, 301/496-7056 ext. 282
This invention is a vaccine for the prevention of disease caused by nontypeable H. influenzae, which causes 25-40% of otitis media cases (middle ear infections) in children and other respiratory tract diseases in humans. The emergence of antibiotic-resistant bacteria has caused concern that treatment of otitis media will become more problematic. This invention offers a new approach to managing otitis media. The vaccine is composed of lipooligosaccharide, isolated from the surface of strains of nontypeable H. influenzae and treated with hydrazine to remove esterified fatty acids, covalently conjugated to an immunogenic carrier, such as tetanus toxoid. The conjugates have been shown to be nontoxic by the limulus amebocyte assay, rabbit pyrogen test, and in a mouse lethal toxicity test. Antisera raised in rabbits immunized with the conjugate is bactericidal. (portfolio: Infectious Diseases - Vaccines, bacterial)
Materials And Methods For Detection And Treatment Of Insulin Dependent Diabetes
NK Maclaren, AL Notkins, Q Li, MS Lan (NIDR)
Serial No. 08/514,213 filed 11 Aug 95 and
Serial No. 08/548,159 filed 25 Oct 95
Licensing Contact: J. Peter Kim, 301/496-7056 ext. 264
Insulin-dependent diabetes mellitus (IDDM) affects close to one million people in the United States. It is an autoimmune disease in which the immune system produces antibodies that attack the body's own insulin-manufacturing cells in the pancreas. Patients require daily injections of insulin to regulate blood sugar levels. The invention identified two proteins, named IA-2 and IA-2b, that are important markers for type I (juvenile, insulin-dependent) diabetes. IA-2/IA-2b, when used in diagnostic tests, recognized autoantibodies in 70 percent of IDDM patients. Combining IA-2/IA-2b with other known markers increased the level of identification to 90 percent of individuals with IDDM. Moreover, the presence of autoantibodies to IA-2/IA-2b in otherwise normal individuals was highly predictive in identifying those at risk of ultimately developing clinical disease. It is now possible to develop a rapid and effective test that can screen large populations for IDDM. In addition, IA-2/IA-2b are candidates for immune tolerance and prevention of disease development.
Compositions Comprising Vitamin F
C Weinberger, S Kitareewan (NIEHS)
Serial No. 60/003,443 filed 08 Sep 95; PCT/US96/15205 filed 06 Sep 96
Licensing Contact: Carol Lavrich, 301/496-7056 ext. 287
This invention relates to a collection of potential fat-soluble vitamins that may coordinate animal metabolism and development. RXR is a nuclear receptor that plays a central role in cell signaling by heterodimerizing with receptors binding thyroid hormones, retinoids and vitamin D. The invention and others of its compositions can be characterized as likely physiological effectors that may represent essential components for human nutrition and cell growth. Thus, the invention suggests that it may coordinate cell physiology through RXR-dependent hormone signaling pathways.
Macrocyclic Chelates, And Methods Of Use Thereof
OA Gansow, K Kumar (NCI)
Serial No. 08/140,714 filed 22 Oct 93
U.S. Patent 5,428,154 issued 27 Jul 95
Licensing Contact: Raphe Kantor, 301/496-7735 ext. 247
Substituted 1,4,7,10-tetraaza cyclododecane-N,N/,N//,N///-tetraacetic acid (DOTA) has numerous desirable chelating qualities that make it useful for treating a number of cellular disorders. Presently available chelating agents lack specificity for their intended targets or do not adequately bind the chelated metal ion. These substituted DOTAs have a strong affinity for a number of metal ions. They can also be linked to biomolecules to form systems for delivering the chelated metal ion, which can be radiolabeled, to specific sites within a cell or organelle. (portfolio: Cancer - Therapeutics, immunoconjugates, conjugate chemistry)
The Cloning Of Perilipin Proteins
C Londos, AS Greenberg, AR Kimmel, JJ Egan (NIDDK)
Serial No. 08/132,649 filed 04 Oct 93
U.S. Patent 5,585,462 to issue 17 Dec 96
Licensing Contact: Ken Hemby, 301/496-7735 ext. 265
Perilipins are found at the surface of lipid storage droplets of adipocytes. Little is known about the molecules on the surface of lipid droplets that may be involved in lipid metabolism and trafficking. The present invention provides isolated nucleic acid sequences which encode a family of perilipin proteins as well as isolated, purified perilipin proteins. These are useful as markers for differentiation of true adipocyte cells from non-adipocyte cells which, as a result of pathophysiological conditions, assume adipocyte characteristics. (portfolio: Cancer - Research Materials)